

# Spectrum of Fibrotic Lung Diseases

New England Journal of Medicine

383, 2485-2486

DOI: [10.1056/nejmc2031135](https://doi.org/10.1056/nejmc2031135)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101272.	0.2	3
2	Home monitoring for patients with ILD and the COVID-19 pandemic. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1172-1174.	5.2	29
3	Spectrum of Fibrotic Lung Diseases. <i>New England Journal of Medicine</i> , 2020, 383, 2485-2486.	13.9	221
4	Molecular approach to the classification of chronic fibrosing lung disease—there and back again. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 89-99.	1.4	1
5	NO-sensitive guanylyl cyclase in the lung. <i>British Journal of Pharmacology</i> , 2021, , .	2.7	8
6	Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662110397.	1.0	11
7	Concurrence of 1- and 3-Min Sit-to-Stand Tests with the 6-Min Walk Test in Idiopathic Pulmonary Fibrosis. <i>Respiration</i> , 2021, 100, 571-579.	1.2	4
8	Editorial: Interstitial Lung Disease in the Context of Systemic Disease: Pathophysiology, Treatment and Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 644075.	1.2	2
9	Genetic Deletion of Polo-Like Kinase 2 Induces a Pro-Fibrotic Pulmonary Phenotype. <i>Cells</i> , 2021, 10, 617.	1.8	8
10	Computed Tomography Findings as Determinants of Local and Systemic Inflammation Biomarkers in Interstitial Lung Diseases: A Retrospective Registry-Based Descriptive Study. <i>Lung</i> , 2021, 199, 155-164.	1.4	5
13	Preoperative pirfenidone in idiopathic pulmonary fibrosis: A wound and injury enigma. <i>Respirology</i> , 2021, 26, 524-526.	1.3	0
15	Aberrant B Cell Receptor Signaling in Na <sup>+</sup> -ve B Cells from Patients with Idiopathic Pulmonary Fibrosis. <i>Cells</i> , 2021, 10, 1321.	1.8	12
16	Severe pulmonary toxicity associated with inhalation of pyrethroid-based domestic insecticides (Bop/Sapolio): a case series and literature review. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 271-277.	1.2	11
17	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. <i>European Respiratory Review</i> , 2021, 30, 210026.	3.0	17
18	MCTR1 Intervention Reverses Experimental Lung Fibrosis in Mice. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1873-1881.	1.6	10
19	Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). <i>Respiratory Research</i> , 2021, 22, 162.	1.4	31
20	Use of Nintedanib and Pirfenidone in Non-Idiopathic Pulmonary Fibrosis Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 92-94.	2.5	2
21	Update in Interstitial Lung Disease 2020. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1343-1352.	2.5	21

#	ARTICLE	IF	CITATIONS
22	Familial Pulmonary Fibrosis. <i>Chest</i> , 2021, 160, 1764-1773.	0.4	21
23	Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 396-404.	1.2	16
24	Pathophysiological Roles of Stress-Activated Protein Kinases in Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6041.	1.8	20
25	Diagnostic Classification of Interstitial Lung Disease in Clinical Practice. <i>Clinics in Chest Medicine</i> , 2021, 42, 251-261.	0.8	6
26	Extracellular Vesicles in Organ Fibrosis: Mechanisms, Therapies, and Diagnostics. <i>Cells</i> , 2021, 10, 1596.	1.8	33
27	Diagnosis and Management of Fibrotic Interstitial Lung Diseases. <i>Clinics in Chest Medicine</i> , 2021, 42, 321-335.	0.8	7
28	Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. <i>European Respiratory Review</i> , 2021, 30, 210011.	3.0	104
29	Care Delivery Models and Interstitial Lung Disease. <i>Clinics in Chest Medicine</i> , 2021, 42, 347-355.	0.8	4
30	The Chameleon Behavior of Sarcoidosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2780.	1.0	7
31	Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era. <i>ERJ Open Research</i> , 2021, 7, 00405-2021.	1.1	14
32	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. <i>Respiratory Research</i> , 2021, 22, 202.	1.4	5
33	Chronic fibrosing progressing interstitial lung disease: a decision of Multidisciplinary Expert Board. <i>Pulmonologiya</i> , 2021, 31, 505-510.	0.2	5
34	Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000889.	1.2	2
35	The justification for the progressive fibrotic phenotype. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 363-367.	1.2	7
36	Biopsy in interstitial lung disease: specific diagnosis and the identification of the progressive fibrotic phenotype. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 355-362.	1.2	8
37	Early Intervention of Pulmonary Rehabilitation for Fibrotic Interstitial Lung Disease Is a Favorable Factor for Short-Term Improvement in Health-Related Quality of Life. <i>Journal of Clinical Medicine</i> , 2021, 10, 3153.	1.0	9
38	The progressive fibrotic phenotype in current clinical practice. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 368-373.	1.2	7
39	Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1349-1379.	0.3	293

#	ARTICLE	IF	CITATIONS
40	Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9316.	1.8	11
41	Lung transplantation for interstitial lung disease. <i>European Respiratory Review</i> , 2021, 30, 210017.	3.0	36
42	Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic. <i>Pharmaceuticals</i> , 2021, 14, 819.	1.7	12
43	Clinical Impact of Surgical Lung Biopsy for Interstitial Lung Disease in a Reference Center. <i>Annals of Thoracic Surgery</i> , 2021, , .	0.7	0
44	Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey. <i>Frontiers in Medicine</i> , 2021, 8, 711194.	1.2	8
45	Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity. <i>Stem Cell Research and Therapy</i> , 2021, 12, 471.	2.4	4
46	Mesenchymal stem cell-derived extracellular vesicles in therapy against fibrotic diseases. <i>Stem Cell Research and Therapy</i> , 2021, 12, 435.	2.4	16
47	Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 311-333.	1.0	1
48	Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective. <i>Biomedicines</i> , 2021, 9, 1237.	1.4	10
49	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1065-1076.	5.2	55
50	SSC-ILD mouse model induced by osmotic minipump delivered bleomycin: effect of Nintedanib. <i>Scientific Reports</i> , 2021, 11, 18513.	1.6	7
51	GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro. <i>PLoS ONE</i> , 2021, 16, e0257281.	1.1	5
54	From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?. <i>Translational Research</i> , 2022, 241, 13-24.	2.2	68
55	Antifibrotics in systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101671.	1.4	4
56	Aspectos claves de la Neumología y la Cirugía Torácica sometidos a debate en la era COVID-19. <i>Open Respiratory Archives</i> , 2021, 3, 100123.	0.0	0
57	MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 996-1004.	1.6	17
58	Moving beyond usual interstitial pneumonia to define progressive fibrotic interstitial lung disease. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1087-1089.	5.2	0
59	A call for evidence in connective tissue diseases-associated interstitial lung disease. <i>Joint Bone Spine</i> , 2022, 89, 105274.	0.8	2

#	ARTICLE	IF	CITATIONS
60	Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype. Nauchno-Prakticheskaya Revmatologiya, 2021, 58, 631-636.	0.2	3
61	Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110324.	1.2	30
62	Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity. Drug Safety, 2021, 44, 1179-1191.	1.4	5
63	Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD). Frontiers in Medicine, 2021, 8, 743977.	1.2	11
64	Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients. Biochemical Pharmacology, 2021, 193, 114812.	2.0	40
66	Targeting fatty acid metabolism for fibrotic disorders. Archives of Pharmacal Research, 2021, 44, 839-856.	2.7	17
67	Alveolar Regeneration in COVID-19 Patients: A Network Perspective. International Journal of Molecular Sciences, 2021, 22, 11279.	1.8	7
69	Lung function trajectory in progressive fibrosing interstitial lung disease. European Respiratory Journal, 2022, 59, 2101396.	3.1	40
70	Lung aging and senescence in health and disease. , 2022, , 61-80.		1
71	Advanced In Vitro Lung Models for Drug and Toxicity Screening: The Promising Role of Induced Pluripotent Stem Cells. Advanced Biology, 2022, 6, e2101139.	1.4	10
72	Automatic quantitative computed tomography measurement of longitudinal lung volume loss in interstitial lung diseases. European Radiology, 2022, 32, 4292-4303.	2.3	11
74	Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Lancet Respiratory Medicine, the, 2022, 10, 593-602.	5.2	31
75	Novedades diagn3sticas y terap4uticas en fibrosis pulmonar progresiva. Archivos De Bronconeumologia, 2022, , .	0.4	7
76	The 1-minute sit-to-stand test to detect desaturation during 6-minute walk test in interstitial lung disease. Npj Primary Care Respiratory Medicine, 2022, 32, 5.	1.1	7
77	The Burden of Progressive-Fibrosing Interstitial Lung Diseases. Frontiers in Medicine, 2022, 9, 799912.	1.2	15
78	Outcomes Following Surgical Lung Biopsy for Interstitial Lung Diseases: A Monocenter Experience. Thoracic and Cardiovascular Surgeon, 2022, 70, 583-588.	0.4	3
79	The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 867-869.	2.5	3
80	Anti-Inflammatory, Antioxidant, and Antifibrotic Effects of Gingival-Derived MSCs on Bleomycin-Induced Pulmonary Fibrosis in Mice. International Journal of Molecular Sciences, 2022, 23, 99.	1.8	16

#	ARTICLE	IF	CITATIONS
81	Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management. <i>European Journal of Radiology Open</i> , 2022, 9, 100419.	0.7	21
82	Is there a role for nailfold videocapillaroscopy in interstitial lung disease?. <i>Rheumatology</i> , 2022, , .	0.9	3
83	Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. <i>Respirology</i> , 2022, 27, 294-300.	1.3	15
85	Editorial: Mechanisms of Lung Fibrosis: Is Immunity Back in the Game?. <i>Frontiers in Immunology</i> , 2022, 13, 882979.	2.2	0
86	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 247-259.	2.5	15
87	Circular RNA Methylation: A New Twist in Lung Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 66, 471-472.	1.4	2
88	The Role of the Vascular Niche in Organ Fibrosis and COVID-19-Related Organ Damage and the Countermeasures adopted by Chinese and Western Medicine. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, , 100085.	0.5	0
89	Exosomal let-7i-5p from three-dimensional cultured human umbilical cord mesenchymal stem cells inhibits fibroblast activation in silicosis through targeting TGFBR1. <i>Ecotoxicology and Environmental Safety</i> , 2022, 233, 113302.	2.9	22
90	Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. <i>European Respiratory Journal</i> , 2022, 60, 2102571.	3.1	57
91	Rheumatoid interstitial lung disease in Canterbury New Zealand: prevalence, risk factors and long-term outcomes” protocol for a population-based retrospective study. <i>BMJ Open</i> , 2022, 12, e050934.	0.8	2
92	Mortality Risk From COVID-19 Among Unvaccinated Subjects With Autoimmune Phenotypes of Interstitial Lung Disease. <i>Cureus</i> , 2022, 14, e23808.	0.2	0
93	Chronic Obstructive Pulmonary Disease Combined with Interstitial Lung Disease. <i>Tuberculosis and Respiratory Diseases</i> , 2022, 85, 122-136.	0.7	3
94	Soluble ECM promotes organotypic formation in lung alveolar model. <i>Biomaterials</i> , 2022, 283, 121464.	5.7	16
95	Advances with pharmacotherapy for the treatment of interstitial lung disease. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 483-495.	0.9	0
96	Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries. <i>Frontiers in Medicine</i> , 2021, 8, 729203.	1.2	5
97	The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Idiopathic Pulmonary Fibrosis. <i>Annals of the American Thoracic Society</i> , 2022, 19, 916-924.	1.5	12
98	Developing Pulmonary Rehabilitation for COVID-19: Are We Linked with the Present Literature? A Lexical and Geographical Evaluation Study Based on the Graph Theory. <i>Journal of Clinical Medicine</i> , 2021, 10, 5763.	1.0	2
99	Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. <i>European Respiratory Review</i> , 2021, 30, 210194.	3.0	43

#	ARTICLE	IF	CITATIONS
100	Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease. Case Reports in Pulmonology, 2022, 2022, 1-7.	0.2	1
101	Current perspective of progressive-fibrosing interstitial lung disease. Respiratory Investigation, 2022, 60, 503-509.	0.9	8
102	[Translated article] Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis. Archivos De Bronconeumología, 2022, , .	0.4	0
103	Treatment outcomes of patients with stage <sc>III nonâ€“small cell lung cancer</sc> and interstitial lung diseases receiving intensityâ€“modulated radiation therapy: A singleâ€“center experience of 85 cases. Thoracic Cancer, 2022, , .	0.8	5
104	PEDF is an antifibrosis factor that inhibits the activation of fibroblasts in a bleomycin-induced pulmonary fibrosis rat model. Respiratory Research, 2022, 23, 100.	1.4	9
105	Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures. ERJ Open Research, 2022, 8, 00681-2021.	1.1	3
106	The MIR100HG/miR-29a-3p/Tab1 axis modulates TGF-Î²1-induced fibrotic changes in type II alveolar epithelial cells BLM-caused lung fibrogenesis in mice. Toxicology Letters, 2022, 363, 45-54.	0.4	8
107	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2022, 205, e18-e47.	2.5	780
108	A New Method for the Assessment of Myalgia in Interstitial Lung Disease: Association with Positivity for Myositis-Specific and Myositis-Associated Antibodies. Diagnostics, 2022, 12, 1139.	1.3	5
109	Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges. ERJ Open Research, 2022, 8, 00115-2022.	1.1	13
110	Synthesis and evaluation of new pirfenidone derivatives as anti-fibrosis agents. RSC Advances, 2022, 12, 14492-14501.	1.7	2
111	Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review. Frontiers in Medicine, 2022, 9, .	1.2	14
112	Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases. Advances in Therapy, 2022, 39, 3392-3402.	1.3	12
113	Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study. Respiratory Research, 2022, 23, .	1.4	4
115	Thymus Functionality Needs More Than a Few TECs. Frontiers in Immunology, 0, 13, .	2.2	12
116	Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies. Expert Review of Respiratory Medicine, 2022, 16, 541-553.	1.0	11
118	Role of Ferroptosis in Fibrotic Diseases. Journal of Inflammation Research, 0, Volume 15, 3689-3708.	1.6	10
119	Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review. Journal of Clinical Medicine, 2022, 11, 3835.	1.0	4

#	ARTICLE	IF	CITATIONS
120	Diagnosis and Treatment of Combined Pulmonary Fibrosis and Emphysema in 2022. JAMA - Journal of the American Medical Association, 2022, 328, 69.	3.8	2
121	Long Non-Coding RNAs in Cardiac and Pulmonary Fibroblasts and Fibrosis. Non-coding RNA, 2022, 8, 53.	1.3	2
122	Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality. Science, 2022, 377, 292-297.	6.0	79
123	Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study. European Respiratory Journal, 2023, 61, 2103173.	3.1	3
124	Progressive Pulmonary Fibrosis: Should the Timelines Be Taken Out of the Definition?. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1293-1294.	2.5	8
125	A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases. International Journal of Technology Assessment in Health Care, 2022, 38, .	0.2	2
126	Management of progressive pulmonary fibrosis associated with connective tissue disease. Expert Review of Respiratory Medicine, 2022, 16, 765-774.	1.0	6
127	Targeting ferroptosis as a vulnerability in pulmonary diseases. Cell Death and Disease, 2022, 13, .	2.7	31
128	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis â€“ 2021 update. Full-length version. Respiratory Medicine and Research, 2023, 83, 100948.	0.4	1
129	Towards Treatable Traits for Pulmonary Fibrosis. Journal of Personalized Medicine, 2022, 12, 1275.	1.1	2
130	Interstitial lung diseases. Lancet, The, 2022, 400, 769-786.	6.3	99
131	Pharmacological treatment for connective tissue disease-associated interstitial lung involvement: Protocol for an overview of systematic reviews and meta-analyses. PLoS ONE, 2022, 17, e0272327.	1.1	1
132	Pulmonary hypertension in interstitial lung disease: an area of unmet clinical need. ERJ Open Research, 2022, 8, 00272-2022.	1.1	5
133	Validation of Proposed Criteria for Progressive Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2023, 207, 69-76.	2.5	32
134	<i>MUC5B</i>, telomere length and longitudinal quantitative interstitial lung changes: the MESA Lung Study. Thorax, 2023, 78, 566-573.	2.7	5
135	Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. American Journal of Respiratory and Critical Care Medicine, 2022, 206, e7-e41.	2.5	53
137	Epidemiology and real-life experience in progressive pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2022, 28, 407-413.	1.2	10
139	Antigen avoidance and environmental inhalation challenge for successful diagnosis of fibrotic hypersensitivity pneumonitis mimicking idiopathic pulmonary fibrosis. Respiratory Medicine Case Reports, 2022, 39, 101737.	0.2	0



#	ARTICLE	IF	CITATIONS
140	Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives. <i>European Respiratory Review</i> , 2022, 31, 220003.	3.0	11
141	Scars of COVID-19: A bibliometric analysis of post-COVID-19 fibrosis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	6
142	Role of Circular RNAs in Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10493.	1.8	6
146	Consequences of telomere dysfunction in fibroblasts, club and basal cells for lung fibrosis development. <i>Nature Communications</i> , 2022, 13, .	5.8	12
147	Home monitoring in interstitial lung diseases. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 97-110.	5.2	32
148	Macrophages in intestinal fibrosis and regression. <i>Cellular Immunology</i> , 2022, 381, 104614.	1.4	5
149	A case of severe COVID-19 in a patient with progressive fibrosing interstitial lung disease. <i>Pulmonologiya</i> , 2022, 32, 763-769.	0.2	0
150	The immunoregulatory role of IL-35 in patients with interstitial lung disease. <i>Immunology</i> , 2023, 168, 610-621.	2.0	3
151	Skin disorders and interstitial lung disease: Part I—Screening, diagnosis, and therapeutic principles. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 751-764.	0.6	1
152	E2F1 regulates miR-215-5p to aggravate paraquat-induced pulmonary fibrosis via repressing BMP2 expression. <i>Toxicology Research</i> , 2022, 11, 940-950.	0.9	4
153	Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis. <i>Advances in Respiratory Medicine</i> , 2022, 90, 425-450.	0.5	4
154	World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
155	Skin disorders and interstitial lung disease: Part II—The spectrum of cutaneous diseases with lung disease association. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 767-782.	0.6	2
156	Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases—Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
157	Metabolic reprogramming of pulmonary fibrosis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
161	Transforming growth factor- $\beta$ 2 signaling: From tissue fibrosis to therapeutic opportunities. <i>Chemico-Biological Interactions</i> , 2023, 369, 110289.	1.7	39
162	2022 Update of indications and contraindications for lung transplantation in France. <i>Respiratory Medicine and Research</i> , 2023, 83, 100981.	0.4	0
163	Genetics in Idiopathic Pulmonary Fibrosis: A Clinical Perspective. <i>Diagnostics</i> , 2022, 12, 2928.	1.3	6

#	ARTICLE	IF	CITATIONS
164	Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study. <i>ERJ Open Research</i> , 2023, 9, 00423-2022.	1.1	5
165	Role of the occupational disease consultant in the multidisciplinary discussion of interstitial lung diseases. <i>Respiratory Research</i> , 2022, 23, .	1.4	7
166	UHRF1-mediated ferroptosis promotes pulmonary fibrosis via epigenetic repression of GPX4 and FSP1 genes. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	7
167	Editorial: Multidisciplinary approach to interstitial lung disease associated with systemic rheumatic diseases. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
168	Lung Damage in Rheumatoid Arthritis – A Retrospective Study. <i>International Journal of Molecular Sciences</i> , 2023, 24, 28.	1.8	3
169	Progressive pulmonary fibrosis: an expert group consensus statement. <i>European Respiratory Journal</i> , 2023, 61, 2103187.	3.1	25
172	Is Carob Flour Helpful in Reducing Diarrhoea Associated With Nintedanib?. <i>Archivos De Bronconeumologia</i> , 2023, 59, 341-343.	0.4	1
173	Impact of COVID-19 Infection on Patients with Preexisting Interstitial Lung Disease: A Spanish Multicentre Study. <i>Archivos De Bronconeumologia</i> , 2023, 59, 273-276.	0.4	2
174	Deciding a Treatment Plan for an Older Patient With Severe Idiopathic Pulmonary Fibrosis: A Case Report. <i>Cureus</i> , 2023, , .	0.2	0
175	Functional respiratory impairment and related factors in patients with interstitial pneumonia with autoimmune features (IPAF): Multicenter study from NEREA registry. <i>Respiratory Research</i> , 2023, 24, .	1.4	5
177	Interstitial Lung Disease: A Focused Review for the Emergency Clinician. <i>Journal of Emergency Medicine</i> , 2023, , .	0.3	0
178	Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2405.	1.8	5
179	Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting. <i>Medicina (Lithuania)</i> , 2023, 59, 281.	0.8	1
180	Neutrophil extracellular traps and pulmonary fibrosis: an update. <i>Journal of Inflammation</i> , 2023, 20, .	1.5	8
181	Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 1173.	1.0	3
182	Fine-tuning characterization of patients with interstitial pneumonia and an underlying autoimmune disease in real-world practice: We get closer with Nailfold videocapillaroscopy. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	1
183	Occupational Interstitial Lung Diseases. <i>Immunology and Allergy Clinics of North America</i> , 2023, 43, 323-339.	0.7	3
184	Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases. <i>Respiratory Medicine</i> , 2023, 212, 107224.	1.3	1

#	ARTICLE	IF	CITATIONS
185	Comparison of the diagnostic criteria for progressive pulmonary fibrosis in connective tissue disease related interstitial lung disease. <i>Respiratory Medicine</i> , 2023, 212, 107242.	1.3	2
186	Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	3
187	Reply to Kamp <i>et al.</i> : Novel Insight into Pulmonary Fibrosis and Long Covid. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2023, 207, 1108-1108.	2.5	2
188	Metformin attenuates fibroblast activation during pulmonary fibrosis by targeting S100A4 via AMPK-STAT3 axis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	6
189	Targeting the pentraxin 3/CD44 axis: A potential treatment for pulmonary fibrosis. <i>Clinical and Translational Discovery</i> , 2023, 3, .	0.2	0
190	Cellular and Molecular Control of Lipid Metabolism in Idiopathic Pulmonary Fibrosis: Clinical Application of the Lysophosphatidic Acid Pathway. <i>Cells</i> , 2023, 12, 548.	1.8	3
191	The world of rare interstitial lung diseases. <i>European Respiratory Review</i> , 2023, 32, 220161.	3.0	4
192	GROUND GLASS OPACITIES: SIGN OF CAUTION IN TYPICAL INTERSTITIAL PNEUMONIA. <i>Central Asian Journal of Medical Hypotheses and Ethics</i> , 2023, 3, 241-244.	0.2	0
194	Obstructive Sleep Apnea and Longitudinal Changes in Interstitial Lung Imaging and Lung Function: The MESA Study. <i>Annals of the American Thoracic Society</i> , 0, , .	1.5	3
195	Pulmonary sarcoidosis complicated by rheumatoid arthritis in a patient presenting with progressive fibrosing interstitial lung disease and treated with nintedanib: a case report and literature review. <i>Therapeutic Advances in Respiratory Disease</i> , 2023, 17, 175346662311582.	1.0	1
196	Research Progress of Anti-Neutrophil Cytoplasmic Antibodies Associated Vasculitis Secondary Interstitial Lung Disease. <i>Advances in Clinical Medicine</i> , 2023, 13, 3018-3024.	0.0	0
197	Serum Levels of Caspase-Cleaved Cytokeratin-18 in Interstitial Lung Disease Associated with Rheumatoid Arthritis, Dermatomyositis, and Polymyositis. <i>Journal of St Marianna University</i> , 2022, 13, 113-125.	0.1	0
198	Evaluation of Pulmonary Fibrosis Outcomes by Race and Ethnicity in US Adults. <i>JAMA Network Open</i> , 2023, 6, e232427.	2.8	15
199	Interstitial Lung Disease in Mixed Connective Tissue Disease: An Advanced Search. <i>Cureus</i> , 2023, , .	0.2	1
200	Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
201	Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts. <i>Nature Communications</i> , 2023, 14, .	5.8	10
202	SH2 Domain-Containing Phosphatase-SHP2 Attenuates Fibrotic Responses through Negative Regulation of Mitochondrial Metabolism in Lung Fibroblasts. <i>Diagnostics</i> , 2023, 13, 1166.	1.3	0
203	Pulmonary fibrosis model of mice induced by different administration methods of bleomycin. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	7

#	ARTICLE	IF	CITATIONS
204	TGF- $\beta$ 2 as A Master Regulator of Aging-Associated Tissue Fibrosis. , 2023, 14, 1633.		10
206	The prognostic value of gastroesophageal reflux disorder in interstitial lung disease related hospitalizations. Respiratory Research, 2023, 24, .	1.4	2
209	The Syndrome of Combined Pulmonary Fibrosis and Emphysema. , 2023, , 561-588.		0
210	Orphan Lung Diseases: From Definition to Organization of Care. , 2023, , 3-10.		1
211	Idiopathic Pulmonary Fibrosis and the Many Faces of UIP. , 2023, , 549-560.		0
212	Inescapable Fibrosis: The Development of Desquamative Interstitial Pneumonia Post-Lung Transplantation Performed for a Patient with Idiopathic Pulmonary Fibrosis. Case Reports in Transplantation, 2023, 2023, 1-6.	0.1	0
213	Can transbronchial lung cryobiopsy benefit adaptive treatment strategies in connective tissue disease-associated interstitial lung disease?. BMC Pulmonary Medicine, 2023, 23, .	0.8	0
216	Post-COVID-19 Pulmonary Fibrosis: Facts&quot;Challenges and Futures: A Narrative Review. Pulmonary Therapy, 2023, 9, 295-307.	1.1	10